Vaginitis refers to the inflammation of
vagina. It affects women of all ages but is most common during the reproductive
years. Vaginitis occurs due to change in the balance of the yeast and bacteria
that normally live in the vagina.
Access
Detailed Report Summary: https://www.pharmaproff.com/report/vaginitis-therapeutics-pipeline-analysis
This causes
the lining of the vagina to become inflamed. Use of antibiotics, changes in
hormone levels due to pregnancy, breastfeeding, menopause, douching,
spermicides, sexual intercourse and infection can change the normal balance of
the vagina. The main symptom of vaginitis is increased discharge with a strong
fishy odour. Itching is not common, but may be present if there is a lot of
discharge.
Request
to Get the Sample Pages at: https://www.pharmaproff.com/request-sample/1151
Vaginitis
can be diagnosed by taking a sample of the discharge from vagina, which is then
observed under a microscope. The treatment depends on the cause of the
vaginitis. It may include a pill or a cream or gel that is applied to the
vagina.
The drug
candidates in vaginitis pipeline include, but are not limited to, Polygynax and
Tamoxifen vaginal. Some of the companies in vaginitis therapeutics pipeline are
Lumavita AG and Fulhold Pharma Limited.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment